Skip to content
Subscriber Only

Russian Vaccine Team in Talks With China on Combination Trial

  • RDIF has preliminary agreement with CanSino, Petrovax
  • Combinations may boost protection, ease production challenges
Researchers are looking at whether combining different developers’ vaccines in a two-shot regimen produces results that are as good as, or better than, using the same product as a booster.

Researchers are looking at whether combining different developers’ vaccines in a two-shot regimen produces results that are as good as, or better than, using the same product as a booster.

Photographer: Andrey Rudakov/Bloomberg

Fresh off global validation of their Covid-19 vaccine’s extraordinary effectiveness, Russian developers are in talks with China’s CanSino Biologics Inc. to test a combined regimen of their shots to better protect against new virus strains, according to people with knowledge of the matter.

The Russian Direct Investment Fund, a partner in the Sputnik V vaccine program, forged a preliminary agreement with the Tianjin-based vaccine developer and Petrovax Pharm Llc, owned by billionaire Vladimir Potanin, to conduct tests in Russia, four people said, declining to be identified as the information isn’t public. Petrovax is Cansino’s Russian partner.